This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Smith, B. B. Articles by Davis, H. Search for Related Content PubMed PubMed Citation Articles by Smith, B. B. Articles by Davis, H. Social Bookmarking                         What's this?

A Toxicity Profile of Osteoprotegerin in the Cynomolgus Monkey

Amgen, Inc., Thousand Oaks, California, USA

Mary Ellen Cosenza

Amgen, Inc., Thousand Oaks, California, USA

Audrey Mancini

Amgen, Inc., Thousand Oaks, California, USA

Colin Dunstan

Amgen, Inc., Thousand Oaks, California, USA

Richard Gregson

Clin Trials Bio Research Ltd., Montreal, Quebec, Canada

Steven W. Martin

Clin Trials Bio Research Ltd., Montreal, Quebec, Canada

Susan Y. Smith

Amgen, Inc., Thousand Oaks, California, USA

Harold Davis

Amgen, Inc., Thousand Oaks, California, USA

Osteoprotegerin (OPG) is a novel secreted glycoprotein of the tumor necrosis factor (TNF) receptor superfamily that acts as an antiresorptive agent inhibiting osteoclast maturation. OPG acts by competitively inhibiting the association of the OPG ligand with the RANK receptor on osteoclasts and osteoclast precursors. This inhibition of osteoclasts can lead to excess accumulation of newly synthesized bone and cartilage in vivo. The purpose of this study was to investigate the potential toxicity of a human recombinant form of OPG in the young cynomolgus monkey. OPG was administered by intravenous (IV) or subcutaneous (SC) injection three times per week for either 4 or 13 weeks. There were no deaths during the study, no clinical signs related to treatment, no effect on body weight, appetence, or ophthalmology. No toxicologically relevant changes in routine laboratory investigations, organ weights, or gross or histopathological findings were observed. Serum ionized calcium and phosphorus were decreased at all dose levels. Evaluations were performed to monitor biochemical markers of bone resorption (N-telopeptide [NTx], deoxypyridinoline [DPD]), bone formation (skeletal alkaline phosphatase [s ALP], osteocalcin [OC]), parathyroid hormone [PTH], and bone density of the proximal tibia and distal radius in vivo. Dose-related decreases in NTx and/or DPD were observed at each dose level, with up to a 90% decrease in NTx noted for animals treated IV or SC at 15 mg/kg. Similar decreases were observed for s ALP and OC. PTH was increased for animals treated at 5 and 15 mg/kg (IV or SC). Trabecular bone density was increased for the majority of males and females treated IV or SC at 15 mg/kg and males treated IV at 5 mg/kg. Microscopic examination of the sternebrae revealed corresponding increases in bone. Decreases in markers of bone turnover, and corresponding increases in bone density, were consistent with the pharmacological action of OPG as an osteoclast inhibitor. The no-observable-adverse-effect level (NOAEL) of OPG was 15 mg/kg.

Key Words: Antiresorptive • Cynomolgus Monkey • Osteoporosis • Osteoprotegerin

International Journal of Toxicology, Vol. 22, No. 5, 403-412 (2003)
DOI: 10.1177/109158180302200512


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?